ANTISCHIZOPHRENIA DRUG TRIALS SHOULD EXAMINE NEGATIVE SYMPTOMS OF DISEASE, ADVISORY CMTE. MEMBERS SUGGEST IN WORKSHOP ON ANTIPSYCHOTIC DEVELOPMENT
Executive Summary
Antipsychotic drug trials should focus more on "negative" symptoms of schizophrenia, members of FDA's Psychopharmacological Drugs Advisory Committee agreed during a workshop on antipsychotic drug development July 24-25.